Phase 2Completed
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
- Sponsor
- Rebiotix Inc. (Industry)
- Enrollment
- 272 enrolled
- Conditions
- Clostridium Difficile Infection
- Interventions
- RBX2660; Standard of Care Antibiotics
- Ages
- adults, older adults
- Registry
- NCT02589847
Full record on ClinicalTrials.gov
From the registry
This study will evaluate efficacy and safety information about RBX2660 for the treatment of recurrent Clostridium difficile infection (CDI), and will compare the efficacy of one treatment with RBX2660 versus antibiotic-treated historical controls. Enrolled subjects will receive one treatment consisting of two doses of RBX2660 (microbiota suspension).
Primary outcomes
- Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks
History
Last registry update
Results first posted
Study completion
Primary completion
Registered
Started